These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 9679965)
1. Galectin-3 is a presurgical marker of human thyroid carcinoma. Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965 [TBL] [Abstract][Full Text] [Related]
2. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421 [TBL] [Abstract][Full Text] [Related]
3. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294 [TBL] [Abstract][Full Text] [Related]
4. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Kawachi K; Matsushita Y; Yonezawa S; Nakano S; Shirao K; Natsugoe S; Sueyoshi K; Aikou T; Sato E Hum Pathol; 2000 Apr; 31(4):428-33. PubMed ID: 10821488 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies. Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419 [TBL] [Abstract][Full Text] [Related]
9. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177 [TBL] [Abstract][Full Text] [Related]
10. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687 [TBL] [Abstract][Full Text] [Related]
11. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007 [TBL] [Abstract][Full Text] [Related]
12. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634 [TBL] [Abstract][Full Text] [Related]
13. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653 [TBL] [Abstract][Full Text] [Related]
14. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475 [TBL] [Abstract][Full Text] [Related]
15. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 is not useful in thyroid FNA. Mills LJ; Poller DN; Yiangou C Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608 [TBL] [Abstract][Full Text] [Related]
17. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105 [TBL] [Abstract][Full Text] [Related]
18. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. Saggiorato E; Cappia S; De Giuli P; Mussa A; Pancani G; Caraci P; Angeli A; Orlandi F J Clin Endocrinol Metab; 2001 Nov; 86(11):5152-8. PubMed ID: 11701669 [TBL] [Abstract][Full Text] [Related]
19. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Aron M; Kapila K; Verma K Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Xu XC; el-Naggar AK; Lotan R Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]